Britain and America have announced a major trade agreement that will keep zero import taxes on UK pharmaceutical exports going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to boost funding on drugs through the National Health Service (NHS). This commitment guarantees that duties on these key products will be held at nothing for a period of three years.
This agreement is in response to earlier warnings to dramatically increase tariffs on branded drug imports, with potential rates floated as high as double the cost.
"This deal with the United Kingdom bolsters the worldwide climate for innovative medicines and establishes much-needed balance to U.S.–U.K. drug exports," an announcement noted.
Trade Importance
Medicines are one of the the United Kingdom's most significant goods shipped to the US, which is by far the biggest destination for leading British pharmaceutical firms.
Export figures indicate that in the year prior to last September, the UK shipped medicines totaling £11.1bn to the US. This amount accounted for nearly one-fifth of total UK exports in that span.
"This deal protects work, stimulates capital expenditure and facilitates the UK to become a global hub for biotech and pharma," a government official remarked.
Key British Pledges
The pact entails several notable commitments from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments topped twenty percent.
Industry Background
The pact follows a protracted row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
This friction were intensified by claims that American patients were charged several times more for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been announced toward American operations.
One official publicly accepted that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a share of its total funding over the previous ten-year period.
